Compare ATRC & ANAB Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | ATRC | ANAB |
|---|---|---|
| Founded | 2000 | 2005 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Medical/Dental Instruments | Biotechnology: Pharmaceutical Preparations |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.4B | 1.3B |
| IPO Year | 2005 | 2015 |
| Metric | ATRC | ANAB |
|---|---|---|
| Price | $28.41 | $54.24 |
| Analyst Decision | Strong Buy | Buy |
| Analyst Count | 7 | 12 |
| Target Price | $51.17 | ★ $71.67 |
| AVG Volume (30 Days) | ★ 692.6K | 482.8K |
| Earning Date | 05-05-2026 | 05-08-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | 74.74 | ★ 91.02 |
| EPS | ★ N/A | N/A |
| Revenue | $201,630,000.00 | ★ $234,603,000.00 |
| Revenue This Year | $15.27 | N/A |
| Revenue Next Year | $12.21 | $52.14 |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | 15.40 | ★ 157.01 |
| 52 Week Low | $25.36 | $17.11 |
| 52 Week High | $43.18 | $73.30 |
| Indicator | ATRC | ANAB |
|---|---|---|
| Relative Strength Index (RSI) | 53.21 | 43.43 |
| Support Level | $28.03 | $53.46 |
| Resistance Level | $30.49 | $57.70 |
| Average True Range (ATR) | 1.20 | 2.61 |
| MACD | 0.09 | -0.14 |
| Stochastic Oscillator | 70.72 | 35.23 |
AtriCure Inc is an innovator in surgical treatments and therapies for atrial fibrillation (Afib), left atrial appendage (LAA) management, and post-operative pain management, and sells its products to medical centers through its direct sales force and distributors. Its product line includes Cryo, Soft Tissue Dissection, RF Ablation, Pacing and Sensing, and others. Geographically, it generates a majority of its revenue from the United States. Cardiac ablation and left atrial appendage management (LAAM) products are used by physicians during open-heart and minimally invasive surgical procedures. Pain management solutions are used by physicians to freeze nerves during cardiothoracic or thoracic surgical procedures.
AnaptysBio Inc is a clinical-stage biotechnology company. The company is focused on developing antibody product candidates for unmet medical needs in inflammation and immuno-oncology. The company is developing immune cell modulating antibodies, including two wholly owned checkpoint agonists in clinical-stage development, for autoimmune and inflammatory diseases; rosnilimab, PD-1 agonist in a Phase 2b trial for the treatment of moderate-to-severe rheumatoid arthritis (RA) and a Phase 2 trial for the treatment of moderate-to-severe ulcerative colitis (UC); and ANB032, BTLA agonist, in a Phase 2b trial for the treatment of moderate-to-severe atopic dermatitis (AD).